AORT — what changed in the latest 10-Q
A section-by-section comparison of AORT's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-08 vs the prior 10-Q · 2025-11-07
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +38 | −50 | ~10 | 19 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~1 | 0 |
| Controls & procedures | Text added/removed | +1 | −1 | ~3 | 0 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 2 |
| Risk factors | Text added/removed | 0 | 0 | ~22 | 152 |
| Other information | Text added/removed | +1 | −2 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-08
Revenues increased 18% for the three months ended March 31, 2026, as compared to the three months ended March 31, 2025. The increase in revenues for the three months ended March 31, 2026 was due to an increase in revenues from aortic stent grafts, preservation services, On-X products, and surgical s…
A detailed discussion of the changes in product revenues and preservation services revenues for the three months ended March 31, 2026 is presented below.
Revenues from products increased 16% for the three months ended March 31, 2026, as compared to the three months ended March 31, 2025. The increase for the three months ended March 31, 2026 was due to an increase in revenues from aortic stent grafts, On-X products, and surgical sealants, partially of…
Sales of certain products through our direct sales force and distributors across Europe and various other countries are denominated in a variety of currencies including Euros, Brazilian Reals, Polish Zlotys, British Pounds, Canadian Dollars, and Swiss Francs with a concentration denominated in Euros…
Constant currency revenues from the sales of aortic stent grafts increased 10% for the three months ended March 31, 2026, as compared to the three months ended March 31, 2025. Revenues for the three months ended March 31, 2026 increased primarily in North America, and Europe, the Middle East, and Af…
Text removed vs the prior filing · source: 10-Q · 2025-11-07
Revenues increased 18% and 12% for the three and nine months ended September 30, 2025, respectively, as compared to the three and nine months ended September 30, 2024. The increase in revenues for the three months ended September 30, 2025 was due to an increase in revenues from aortic stent grafts, …
US GAAPUS GAAPExchange Rate EffectConstant CurrencyConstant Currency
A detailed discussion of the changes in product revenues and preservation services revenues for the three and nine months ended September 30, 2025 is presented below.
Revenues from products increased 23% and 18% for the three and nine months ended September 30, 2025, respectively, as compared to the three and nine months ended September 30, 2024. The increase for the three months ended September 30, 2025 was due to an increase in revenues from aortic stent grafts…
Sales of certain products through our direct sales force and distributors across Europe and various other countries are denominated in a variety of currencies including Euros, Brazilian Reals, Polish Zlotys, British Pounds, Canadian Dollars, and Swiss Francs with a concentration denominated in Euros…
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-05-08
During the three months ended March 31, 2026, we upgraded our German Enterprise Resource Planning (“ERP”) system, effective January 1, 2026. During the three months ended March 31, 2026, there have been no changes, including any changes related to the upgrade of the ERP system, that have materially …
Text removed vs the prior filing · source: 10-Q · 2025-11-07
There were no changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal controls over finan…
Other information
Text added vs the prior filing · source: 10-Q · 2026-05-08
No directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified, or terminated the contracts, instructions, or written plans for the purchase or sale of the Company’s securities during the three months ended March 31, 2026.
Text removed vs the prior filing · source: 10-Q · 2025-11-07
On August 14, 2025 John E. Davis, our Chief Commercial Officer, adopted a Rule 10b5-1 trading arrangement, pursuant to which he may sell up to 12,787 shares of the Company's common stock. The duration of the trading arrangement is from November 14, 2025 to March 5, 2026. On August 14, 2025 Jean F. H…
No other directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified, or terminated the contracts, instructions, or written plans for the purchase or sale of the Company’s securities during the three months ended September 30, 2025.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice